INTRODUCTION: Selective IgA deficiency (IgAD; serum IgA concentration of <0.07 g/l) is the most common primary immunodeficiency in Caucasians with an estimated prevalence of 1/600. The frequency of the extended major histocompatibility complex haplotype HLA A1, B8, DR3, DQ2 (the "8.1" haplotype) is increased among patients with IgAD. MATERIALS AND METHODS: We carried out a direct measurement of the relative risk of homozygosity of the 8.1 haplotype for IgA deficiency in a population-based sample of 117 B8, DR3 homozygous individuals. RESULTS AND DISCUSSION: IgA deficiency was found to be present in 2 of 117 (1.7%) of these subjects, a figure that is concordant with estimates of relative risk from large case-control studies in the Swedish population. These data are consistent with a multiplicative model for the 8.1 haplotype contribution to IgA deficiency and contrasts with prior studies, suggesting a much higher risk for 8.1 homozygosity. Using a dense single nucleotide polymorphism marker analysis of the MHC region in HLA B8, DR3, DQ2 homozygous individuals, we did not observe consistent differences between cases (n = 26) and controls (n = 24). Overall, our results do not support the hypothesis that IgA deficiency is associated with a distinct subgroup of 8.1 related haplotypes, but rather indicate that risk is conferred by the common 8.1 haplotype acting in multiplicative manner.
INTRODUCTION: Selective IgA deficiency (IgAD; serum IgA concentration of <0.07 g/l) is the most common primary immunodeficiency in Caucasians with an estimated prevalence of 1/600. The frequency of the extended major histocompatibility complex haplotype HLA A1, B8, DR3, DQ2 (the "8.1" haplotype) is increased among patients with IgAD. MATERIALS AND METHODS: We carried out a direct measurement of the relative risk of homozygosity of the 8.1 haplotype for IgA deficiency in a population-based sample of 117 B8, DR3 homozygous individuals. RESULTS AND DISCUSSION: IgA deficiency was found to be present in 2 of 117 (1.7%) of these subjects, a figure that is concordant with estimates of relative risk from large case-control studies in the Swedish population. These data are consistent with a multiplicative model for the 8.1 haplotype contribution to IgA deficiency and contrasts with prior studies, suggesting a much higher risk for 8.1 homozygosity. Using a dense single nucleotide polymorphism marker analysis of the MHC region in HLA B8, DR3, DQ2 homozygous individuals, we did not observe consistent differences between cases (n = 26) and controls (n = 24). Overall, our results do not support the hypothesis that IgA deficiency is associated with a distinct subgroup of 8.1 related haplotypes, but rather indicate that risk is conferred by the common 8.1 haplotype acting in multiplicative manner.
Authors: J E Volanakis; Z B Zhu; F M Schaffer; K J Macon; J Palermos; B O Barger; R Go; R D Campbell; H W Schroeder; M D Cooper Journal: J Clin Invest Date: 1992-06 Impact factor: 14.808
Authors: M Frankowiack; R-M Kovanen; G A Repasky; C K Lim; C Song; N L Pedersen; L Hammarström Journal: Genes Immun Date: 2015-01-08 Impact factor: 2.676
Authors: Ryan Ramanujam; Fredrik Piehl; Ritva Pirskanen; Peter K Gregersen; Lennart Hammarström Journal: J Neuroimmunol Date: 2011-06-12 Impact factor: 3.478
Authors: Ning Wang; Nan Shen; Timothy J Vyse; Vidya Anand; Iva Gunnarson; Gunnar Sturfelt; Solbritt Rantapää-Dahlqvist; Kerstin Elvin; Lennart Truedsson; Bengt A Andersson; Charlotte Dahle; Eva Ortqvist; Peter K Gregersen; Timothy W Behrens; Lennart Hammarström Journal: Mol Med Date: 2011-08-04 Impact factor: 6.354
Authors: Ricardo C Ferreira; Qiang Pan-Hammarström; Robert R Graham; Gumersindo Fontán; Annette T Lee; Ward Ortmann; Ning Wang; Elena Urcelay; Miguel Fernández-Arquero; Concepción Núñez; Gudmundur Jorgensen; Björn R Ludviksson; Sinikka Koskinen; Katri Haimila; Leonid Padyukov; Peter K Gregersen; Lennart Hammarström; Timothy W Behrens Journal: PLoS Genet Date: 2012-01-26 Impact factor: 5.917
Authors: Amir Amanzadeh; Ali Akbar Amirzargar; Nilufar Mohseni; Zohreh Arjang; Asghar Aghamohammadi; Mohammad Ali Shokrgozar; Fazel Shokri Journal: Avicenna J Med Biotechnol Date: 2012-04